Hypertrophic cardiomyopathy (HCM) is a disease involving the cardiac sarcomere. It is
associated with various disease-causing gene mutations and phenotypic expressions,
managed with different therapies with variable prognoses. The heterogeneity of the disease
is evident in the fact that it burdens patients of all ages. HCM is the most prevalent cause of
sudden death in athletes. However, several technological advancements and therapeutic
options have reduced mortality in patients with HCM to 0.5% per year. In addition, rapid …